Cargando…
Treating non-responders: pitfalls and implications for cancer immunotherapy trial design
BACKGROUND: Conventional trial design and analysis strategies fail to address the typical challenge of immune-oncology (IO) studies: only a limited percentage of treated patients respond to the experimental treatment. Treating non-responders, we hypothesize, would in part drive non-proportional haza...
Autores principales: | Xu, Zhenzhen, Park, Yongsoek, Liu, Ke, Zhu, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071722/ https://www.ncbi.nlm.nih.gov/pubmed/32171307 http://dx.doi.org/10.1186/s13045-020-0847-x |
Ejemplares similares
-
Lung cancer immunotherapy: progress, pitfalls, and promises
por: Lahiri, Aritraa, et al.
Publicado: (2023) -
Pitfalls in the radiological response assessment of immunotherapy
por: Beer, Lucian, et al.
Publicado: (2018) -
MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives
por: Aquino, Domenico, et al.
Publicado: (2017) -
Non-adherence in non-inferiority trials: pitfalls and recommendations
por: Mo, Yin, et al.
Publicado: (2020) -
Non-adherence in non-inferiority trials: pitfalls and recommendations
Publicado: (2020)